衰老關(guān)鍵蛋白3(FBLN3)檢測試劑盒(化學發(fā)光免疫分析法)
CLIA Kit for Fibulin 3 (FBLN3)
EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5
- 編號SCF422Hu
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長2h, 40min
- 檢測范圍0.14-100ng/mL
- 靈敏度最小可檢測劑量小于等于0.07ng/mL.
- 樣本類型Serum, plasma, urine and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格48T96T96T*596T*1096T*100
- 價格¥ 3528¥ 5040¥ 22680¥ 42840¥ 352800
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實驗結(jié)果圖
標準曲線圖
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
本試劑盒用于檢測衰老關(guān)鍵蛋白3(FBLN3)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的衰老關(guān)鍵蛋白3(FBLN3)（加標樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 96-105 | 101 |
| EDTA plasma(n=5) | 98-105 | 102 |
| heparin plasma(n=5) | 86-101 | 91 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的衰老關(guān)鍵蛋白3(FBLN3)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中衰老關(guān)鍵蛋白3(FBLN3)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 79-95% | 98-105% | 90-101% | 86-97% |
| EDTA plasma(n=5) | 91-99% | 97-105% | 88-102% | 86-99% |
| heparin plasma(n=5) | 80-101% | 84-94% | 98-105% | 87-98% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本的準備；
2. 加樣（標準品及樣本）100µL，37°C孵育1小時；
3. 吸棄，加檢測溶液A100μL，37°C孵育1小時；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加底物100µL，37°C孵育10分鐘；
8. 讀數(shù)。
實驗原理
將衰老關(guān)鍵蛋白3(FBLN3)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標準品或標本，其中的衰老關(guān)鍵蛋白3(FBLN3)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的衰老關(guān)鍵蛋白3(FBLN3)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標記的親和素，再次徹底洗滌后加入底物。加入底物后會產(chǎn)生輝光型光信號。發(fā)射光強度和樣品中的衰老關(guān)鍵蛋白3(FBLN3)呈正相關(guān)。用化學發(fā)光儀測定相對光單位（RLU），計算樣品濃度。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPF422Hu02 | 衰老關(guān)鍵蛋白3(FBLN3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPF422Hu01 | 衰老關(guān)鍵蛋白3(FBLN3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAF422Hu01 | 衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體 | WB; IHC; ICC; IP. |
| PAF422Hu02 | 衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體 | WB |
| LAF422Hu71 | 衰老關(guān)鍵蛋白3(FBLN3)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| MAF422Hu23 | 衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體 | WB |
| MAF422Hu24 | 衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體 | WB |
| MAF422Hu22 | 衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體 | WB |
| MAF422Hu25 | 衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體 | WB |
| MAF422Hu21 | 衰老關(guān)鍵蛋白3(FBLN3)單克隆抗體 | WB |
| SEF422Hu | 衰老關(guān)鍵蛋白3(FBLN3)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCF422Hu | 衰老關(guān)鍵蛋白3(FBLN3)檢測試劑盒(化學發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMF422Hu | 衰老關(guān)鍵蛋白3(FBLN3)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| 1 | Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma[PubMed: PMC3761217] |
| Anticancer Res. | YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.[Pubmed: 24324091] |
| Oncology Reports | Role of fibulin-3 in lung cancer: In vivo and in vitro analyses[Spandidos-publications: Source] |
| Current Pulmonology Reports | Discovery of new biomarkers for malignant mesothelioma[Springer:Source] |
| United States Patent Application 20140378336 | DIAGNOSIS OF CELL PROLIFERATIVE DISEASES[Freepatentsonline:Source] |
| Thorax. | Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma[Pubmed:Pmc4174124] |
| Egyptian Journal of Chest Diseases and Tuberculosis | Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions[Pubmed:23050525] |
| Radiol Oncol | Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma[PubMed: 26401134] |
| British Journal of Cancer | Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis[PubMed: 26263483] |
| J Thorac Oncol. | Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.[Pubmed:26903362] |
| BMJ Open | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study [pubmed:27884852] |
| 25 | HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients[pubmed:26733616] |
| BMJ Journals | Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational …[e013324.abstract] |
| Anticancer Res. | Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.[pubmed:28314308] |
| Dis Markers. | A Novel Panel of Serum Biomarkers for MPM Diagnosis.[pubmed:28348450] |
| The Knee | Association of fibulin-3 concentrations with the presence and severity of knee osteoarthritis: A cross-sectional study[pubmed:29195846] |
| Disease markers | Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population[pubmed:29200597] |
| Molecular?Medicine?Reports | Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes[Pubmed:29749501] |
| Oncotarget | The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion[Pubmed:30046386] |
| Advances in?Clinical?and Experimental?Medicine | Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with?…[68362.pdf] |
| PLoS One | Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals[Pubmed: 30946771] |